Detalhe da pesquisa
1.
Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA.
Lancet
; 402(10419): 2307-2316, 2023 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37979595
2.
Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 402(10404): 775-785, 2023 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37516125
3.
Atogepant for the Preventive Treatment of Migraine.
N Engl J Med
; 385(8): 695-706, 2021 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407343
4.
Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.
Cephalalgia
; 43(1): 3331024221128250, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36620892
5.
Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial.
Headache
; 63(1): 79-88, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36651532
6.
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
Cephalalgia
; 42(1): 3-11, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34521260
7.
Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.
Cephalalgia
; 41(9): 979-990, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33874756
8.
Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.
Headache
; 60(1): 141-152, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31913519
9.
Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults.
Cephalalgia
; 39(14): 1753-1761, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31537107
10.
Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
Mov Disord
; 28(14): 1966-71, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24243757
11.
Neuroimaging markers of motor and nonmotor features of Parkinson's disease: an 18f fluorodeoxyglucose positron emission computed tomography study.
Dement Geriatr Cogn Disord
; 35(3-4): 183-96, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23445555
12.
Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial.
Neurology
; 100(8): e764-e777, 2023 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36396451
13.
Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials.
Adv Ther
; 39(1): 692-705, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34874514
14.
Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.
JAMA Netw Open
; 5(6): e2215499, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35675076
15.
LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease.
Mov Disord
; 25(15): 2536-41, 2010 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20818610
16.
It's tricky: Rating alleviating maneuvers in cervical dystonia.
J Neurol Sci
; 419: 117205, 2020 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33160248
17.
Validity of spiral analysis in early Parkinson's disease.
Mov Disord
; 23(4): 531-7, 2008 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18074362
18.
Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.
J Clin Neurosci
; 28: 185-6, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26857292
19.
Clinical and genetic features of cervical dystonia in a large multicenter cohort.
Neurol Genet
; 2(3): e69, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27123488
20.
Digitized spiral analysis is a promising early motor marker for Parkinson Disease.
Parkinsonism Relat Disord
; 16(3): 233-4, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20079674